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Background: The value of elevated serum angiotensin-converting enzyme (ACE) activity in
the diagnosis and follow-up in sarcoidosis is a matter of ongoing debate. This may be at
least related to the insertion (I)/deletion (D) polymorphism in the ACE gene (ACE I/D). ACE
activity is inﬂuenced by the ACE I/D polymorphism. As a consequence, the use of one
reference interval instead of three genotype-speciﬁc reference intervals for ACE activity
may lead to a less precise interpretation of ACE activity.
Methods: In order to assess whether determination of ACE activity indeed requires the
ACE I/D genotype to be taken into account, we established ACE I/D-corrected reference
intervals in healthy, Caucasian volunteers (n ¼ 200). In addition, ACE activities in ACE I/D
genotyped patients suspected of or having sarcoidosis (n ¼ 129) were expressed as the
Z-score related to ACE I/D-corrected reference intervals.
Results: Comparison of the Z-score with ACE activity in which ACE I/D is ignored rendered
8.5% misclassiﬁcation of ‘elevated’ versus ‘normal’ ACE or vice versa.
Conclusions: Our data demonstrate a convenient way to circumvent the use of three
reference intervals by introducing a Z-score for ACE activity. It also illustrates the need to
re-investigating the possible clinical value of serum ACE activity in sarcoidosis by
considering ACE I/D.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
09 9111; fax +31 30 609 2528.
net (H.J.T. Ruven).Background
For at least 25 years, angiotensin-converting enzyme (ACE)
(peptidyl-dipeptidase A, EC 3.4.15.1) measurements in
blood are commonly requested for diagnosis and follow-up
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Z-scores of ACE I/D-corrected ACE activity 511in patients with sarcoidosis. Sarcoidosis is a granulomatous
disease with unknown etiology in which serum ACE activity is
found to be elevated in approximately 60% of the patients.1
However, given the gross inter-individual variation of ACE
levels and the observations that population-based reference
intervals for ACE have been acknowledged as being
deceptive in terms of identifying abnormal values, the
added value of ACE levels in the diagnosis and follow-up of
sarcoidosis is still subject to debate.2,3 Part of this discussion
may ﬁnd its cause in insufﬁcient regard for the contribution
of the most extensively studied ACE gene polymorphism,
namely the ACE I/D polymorphism, into account. Cambien
et al.4 were the ﬁrst to indicate the genetic inﬂuence on ACE
levels by revealing a major quantitative trait locus (QTL)
responsible for nearly half of the variance in serum ACE
levels. This was later identiﬁed as a polymorphism in the
gene encoding for ACE. The polymorphism is caused by an
insertion of a 287 bp fragment within intron 16 and it is
commonly present in various populations.5 An absence of
the inserted fragment is referred to as a deletion and the
two alleles of this polymorphism are denoted I (insertion)
and D (deletion). Homozygous carriers of D (DD) or I (II)
express the highest and lowest ACE levels, respectively, with
intermediate ACE levels for heterozygous ID individuals.6
As reported in other populations, the approach of using
ACE I/D-corrected reference intervals of ACE activity may
improve the interpretation of ACE levels during follow-up
and diagnosis.7–9 ‘Elevated’ versus ‘normal’ ACE activity
which is not based on ACE activity in ACE I/D-characterized
reference populations may introduce a less precise inter-
pretation of ACE activity in a patient suspected of
sarcoidosis who presents for the ﬁrst time. As a conse-
quence, ACE activity may be underestimated in II individuals
and overestimated in DD individuals. On the one hand, the
introduction of three reference intervals for ACE activity,
i.e., II, ID and DD, seems a rather simple approach to
prevent this under- or overestimation. On the other hand,
three reference intervals for one analyte, i.e. ACE, raises
questions about how to report laboratory results in the
(near) future, since an increasing number of reference
intervals of analytes based on genetic polymorphisms can be
expected.
In order to study the relevance of the ACE I/D
polymorphism in the interpretation of ACE activity in
patients suspected of sarcoidosis, we ﬁrst established ACE
I/D-corrected reference intervals in Dutch, white Cauca-
sian, healthy volunteers. Secondly, we introduced the
Z-score approach to report ACE activity based on ACE I/D
polymorphism. The Z-score, or standard score, is a
dimensionless quantity derived by subtracting the popula-
tion mean from an individual (raw) score and then dividing
the difference by the population standard deviation. The
quantity Z represents the distance between the raw score
and the population mean in units of the standard deviation.
Using the Z-score, the ACE activity in patients (raw score) is
reported as the deviation from the mean ACE activity in the
ACE I/D-corrected reference population. This approach may
not only contribute to renewed gathering and evaluation of
data with respect to the role of ACE activity in the diagnosis
and follow-up of sarcoidosis but may also be a pragmatic
way to meet the physician’s future need of reporting analyte
activity based on genotype-corrected reference intervals.Methods
Healthy volunteers and patients
Healthy employees of the St. Antonius Hospital volunteered
for venapunction. Relevant information about medication,
ethnicity and hereditary diseases was obtained by having the
volunteers complete a questionnaire. Non-Caucasian sub-
jects were omitted from further analysis in order to
maintain genetic homogeneity of the population. Subjects
who were treated with medication known to affect the
rennin–angiotensin system, either by directly inhibiting ACE
or angiotensin II type 1 receptor blocking, were also
excluded from our studies to prevent pharmacologically
altered ACE activity. The remaining total of 200 subjects,
used for evaluation and analyses, comprised 100 women
(mean age7SD [range] (years): 39712.4 [18–67]) and 100
men (42710.4 [19–68]). The medical ethical committee of
this hospital approved the study conducted and all subjects
gave formal written consent.
One hundred and twenty-nine ACE measurements from
patients suspected of sarcoidosis or reactivation of pre-
viously diagnosed sarcoidosis were retrospectively evalu-
ated for ACE levels and genotyped for the ACE I/D
polymorphism. The group that was diagnosed with sarcoi-
dosis included 94 Dutch Caucasian patients (53 men/41
women). The diagnosis of sarcoidosis was established when
clinical ﬁndings were supported by histological evidence
and after exclusion of other known causes of granulomatosis
in accordance with the consensus of the ATS/ERS/WASOG
statement on sarcoidosis.10 In nine patients, the diagnosis
was made without biopsy proof because these patients
presented with the classic symptoms of Lo¨fgren’s syn-
drome, namely fever, erythema nodosum, arthralgia and
bilateral hilar lymphadenopathy. Fifteen patients with
sarcoidosis had been diagnosed outside of this hospital
prior to referral. The age at which the initial diagnosis
was made was unknown. Five patients had presented
at our clinic for the ﬁrst time. The mean age7SD [range]
at the time the diagnosis was made was 38.0712.6 [20–81]
years. The remaining 89 sarcoidosis patients had been
clinically monitored for 10 (median); 1–37 (range) years,
after which time ACE activity was being measured.
Chest radiographs were assessed in consensus by chest
physicians specialized in diffuse lung diseases to deter-
mine disease severity using standard radiographic staging
for sarcoidosis, classiﬁed according to the Scadding
criteria.10 Over the median follow-up period of 10 years at
which ACE was measured, 51 patients normalized or
improved towards stage I, 21 patients had persistent
stage II/III or progression towards this stage, and 12 patients
developed ﬁbrosis (stage IV or progressive towards
this stage). The patients who had been diagnosed with
Lo¨fgren’s syndrome (radiographic stage I at presentation).
(n ¼ 9) had received radiographic follow-up of 4 (median);
1–27 (range) years. These patients had normalized chest
radiography in less than 2 years following presentation. At
the time ACE activity was measured, 54 sarcoidosis patients
were receiving treatment with corticosteroids and one
patient with methotrexate. Forty-six patients were cigar-
ette smokers, while the smoking status of 30 patients was
unknown.
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men and 12 women (smokers/non-smokers/unknown: 10/
23/2). None of these patients were taking medication that
directly interferes with the rennin–angiotensin–aldosterone
system such as ACE-inhibitors or angiotensin II receptor
antagonists. Upon histological evaluation, sarcoidosis could
be excluded in 28 patients. The mean age7SD [range]
(years) at the time ACE was measured was 53.1713.4
[26–84]).Genotyping
Genomic DNA of volunteers and patients was isolated from
EDTA blood using the MagNA Pure LC DNA Isolation kit I
(MagNA Pure; Roche Diagnostics).
ACE I/D polymorphisms were determined by real-time
PCR using ﬂuorescent hybridization probes and a LightCycler
(Roche Diagnostics) as described earlier with some slight
modiﬁcations.5,11,12 Brieﬂy, the reaction volume was 20 ml,
containing 1 ml of DNA (40–80 ng), 0.2mM forward primer and
0.8mM reversed primer reported by Rigat et al.,5 2ml of 10x
reaction buffer (LightCycler DNA master hybridization
probes, Roche Diagnostics), 1.6 ml of 25mM MgCl2 stock
solution and 0.1 mM of each of the probes. The detection
probes were the same as described by Somogyva´ri et al.11
The PCR conditions were as follows: denaturation at 95 1C
for 60 s, followed by 50 cycles denaturation (95 1C for 10 s),
annealing (ﬁrst 10 cycles: 67 1C for 20 s, followed by 0.5 1C
stepwise decrease per cycle to 61 1C) and extension (72 1C
for 30 s). Melting curve analysis consisted of heating to 95 1C
for 5 s, 45 1C for 60 s, followed by an increase of the
temperature to 75 1C at 0.2 1C/s. To exclude mistyping of I/D
heterozygotes as D/D homozygotes, a second PCR reaction
was performed under the same conditions except for using
the primer pair described earlier.11,12 Veriﬁcation of the
real-time PCR results with those of electrophoresis and using
SSP-PCR revealed no mistyping.Determination of ACE activity
Quantiﬁcation of ACE activity was measured in lithium
heparin plasma using the Bu¨hlmann ACE kinetic test,
according to previously described methods (Bu¨hlmann
Laboratories AG, Switzerland).13,14 The manufacturer’s
reference interval is 12–68U/l.Table 1 ACE I/D-corrected reference intervals for ACE.
n 200
ACE genotype II
n 43
Mean ACE (SD) 25.9 (8.7)
Calculated reference interval 9–43
ANOVA Po0.0001
Multiple comparisons Po0.001 for II vs. ID;
Mean ACE and reference intervals (+1.96 SD and 1.96 SD reference
One-way ANOVA, followed by Tukey’s post-test was performed for geStatistical analyses
The statistical evaluation of our data was performed using
SPSS 11 (SPSS Inc., Chicago, IL, USA) and Graphpad Prism v. 4
(Graphpad Software, Inc., San Diego, CA, USA) software
packages.
Chi-square test was used for categorical variables and
Student’s t-test or ANOVA, followed by Tukey’s post-test for
multiple comparisons between groups, was used for analysis
of continuous variables that were normally distributed.
Variance analysis was performed and the effect size was
calculated using the omega-squared approach.15 This
equation describes the portion of variance explained by
the ACE I/D genotype and other factors. Fixed factors were
gender and the ACE I/D genotype. Age was included as a
covariate.
Genotype frequencies were tested for Hardy-Weinberg
equilibrium. P values lower than 0.05 were considered
statistically signiﬁcant.
Z-score was calculated as (ACEpatientmean ACEreferencegroup)/
SDreferencegroup, where mean ACEreferencegroup and SDreferencegroup
are calculated from the ACE values measured in either the
II, ID or DD reference group. If z is less than 1.96 below the
mean or z is greater than +1.96 above the mean, the ACE
level value is considered deviant from the reference interval
used.Results
ACE activity and ACE/ I/D genotypes in healthy
volunteers
ACE activity and reference intervals categorized to ACE I/D
genotype were determined in healthy volunteers (Table 1).
Signiﬁcant differences in ACE activity (U/l) between
subjects grouped according to ACE I/D were observed as
follows: II (25.9), ID (38.1) and DD (53.1) (Table 1; ANOVA
Po0.0001). The DD group exhibited ACE levels that reached
twice the value of that of the II group whereas intermediate
values were observed in the ID group. ACE I/D-corrected ACE
values grouped according to sex showed a similar trend
(ANOVA Po0.0001, data not shown). A moderate yet
signiﬁcant difference between ACE levels (mean7SD, range
(U/l) in healthy males (42.5716.5, 11.8–84.1) and females
(36.2713.5, 12.9–79.0) (Po0.001) was observed (Table not
shown).
Variance analysis showed that 34.0% of the variance in
ACE activity was attributed to the ACE I/D genotype.ID DD
107 50
38.1 (12.2) 53.1 (14.9)
14–62 24–82
ID vs. DD and II vs. DD
limits) are shown for each ACE genotype.
notype-corrected ACE levels comparisons.
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activity observed in plasma, ACE activity was also measured
in sera of the healthy population using the Fujirebio test
(Fujirebio Inc., Tokyo, Japan, cat. no. FU 116).16,17 The
results between plasma and serum were identical in terms
of ACE I/D genotype-dependent ACE activity (data not
shown).
ACE I/D allele frequencies in healthy volunteers were
48.2% for I and 51.8% for D whereas ACE I/D genotype
frequencies for II, ID and DD were 21.5%, 53.5% and 25%,
respectively (Table 2). No deviation from the Hardy–Wein-
berg equilibrium was found for the ACE genotypes in the
three populations studied. No signiﬁcant differences were
found for allele, allele carrier or genotype frequencies of
ACE I/D between males and females in healthy volunteers
(Table 2).
Z-scores of patients
In order to demonstrate the consequences of ACE I/D-
corrected reference intervals for the classiﬁcation of ACE in
‘elevated’ versus ‘normal’ ACE activity, 129 ACE measure-
ments in patients suspected of sarcoidosis were calculated
and interpreted in two ways: ACE activity while disregarding
ACE I/D polymorphisms and ACE activity while taking ACE I/
D-corrected reference intervals into account. In the second
approach, ACE activity is reported as the Z-score related to
the three ACE I/D-corrected reference intervals. Using both
approaches, 11 out of 129 measurements (8.5%) were shown
to lead to a different interpretation, i.e. from ‘elevated’ to
‘normal’ or vice versa (Table 3).
Discussion
Discordant classiﬁcation of ACE activity in 11 out of 129
(8.5%) ACE measurements in patients suspected of having
(reactivated) sarcoidosis clearly demonstrates the conse-
quences of the ACE I/D polymorphism on the interpretation
of ACE activity. All elevated ACE levels changing from
‘elevated’ to ‘normal’ were from DD individuals, of whomTable 2 ACE I/D genotype distribution in Dutch Caucasians.
Group Total (n ¼ 200)
Genotype frequency II ID DD
n (%) 43
(21.5)
107
(53.5)
50
(25.0)
Allele carrier frequency I D
n (%) 150
(75.0)
157
(78.5)
Allele frequency I D
n (%) 193
(48.2)
207
(51.8)
w2 (allele carrier, carrier and
genotype frequencies)
P40.05 (not signiﬁcant)
Data are shown as number of individuals (n) in each group, subdi
frequencies are shown as number of individuals (n) and percentag
distributions between genders.two patients had histiocytosis X and extrinsic allergic
alveolitis, respectively. Normal ACE levels changing to
‘elevated’ were from II individuals. ACE measurements in
these individuals, which are used to illustrate the impor-
tance of ACE I/D genotyping clearly show the imprecise
interpretation that can occur if the knowledge of genetic
inﬂuence on ACE levels is ignored.
Compared to females in the control group, males had
slightly higher mean ACE activity, which was not due to
differences in ACE I/D genotype distributions between the
two genders. Although some studies have reported serum
ACE activity to be gender-independent,18,19 other studies
indicate that, for reasons unknown, males have a modestly
higher ACE activity compared to females.20,21 However,
integration of gender in the Z-score calculation did not
change the percentage of patients who were imprecisely
marked as having normal or elevated ACE activity before
genotype correction. Therefore, the gender consideration in
addition to the ACE I/D genotype may not be critical when
reporting ACE values as Z-scores.
The purpose of this study is not to contribute to the
clinical validation of ACE. The patients merely serve to
demonstrate the importance of applying genotype-cor-
rected reference intervals for ACE. Moreover, we regard
the utilization of ACE I/D-corrected reference intervals for
ACE activity as a prerequisite for renewed research to the
relevance of measuring ACE in sarcoidosis. For instance,
previous studies evaluating alternative markers for sarcoi-
dosis disease activity such as soluble interleukin (IL)
receptor-2,22 procollagen 1 and 2,23 IL-12,24 IL-825 and,
more recent,YKL-40,26 have traditionally been benchmarked
against ACE, without correcting the latter for its genotype.
The re-evaluation of these markers by comparing its
performance as a possible marker for sarcoidosis disease
activity with ACE I/D genotype-corrected Z-scores, may
shed a new light on previous ﬁndings. The Z-score approach
may also offer its value in prospective studies or re-
evaluation of studies in which ACE activity has been
measured in the context of other respiratory diseases
including pneumonia,27 asthma,28 tuberculosis,29,30 and
chronic obstructive pulmonary disorder (COPD).29Males (n ¼ 100) Females (n ¼ 100)
II ID DD II ID DD
20
(20.0)
54
(54.0)
26
(26.0)
23
(23.0)
53
(53.0)
24
(24.0)
I D I D
74
(74.0)
80
(80.0)
76
(76.0)
77
(77.0)
I D I D
94
(47.0)
106
(53.0)
99
(0.49)
101
(51.0)
vided according to gender. Genotype, allele carrier and allele
e (%). w2-test was performed to compare allele and genotype
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Table 3 ACE measurements leading to discordant classiﬁcation between two approaches for reporting ACE activity.
Measurement ACE
(U/l)
ACE
genotype
Z-score (based on
conventional
reference
interval)
Z-score (based
on ACE I/D-
corrected
reference
intervals)
Changey Diseasez
1 45 II 0.36 2.20 Elevated Stage II/III sarcoidosis
2 62 II 1.47 4.15 Elevated Stage II/III sarcoidosis
3 63 ID 1.53 2.04 Elevated Stage II/III sarcoidosis
4 65 ID 1.66 2.20 Elevated Stage II/III sarcoidosis
5 65 II 1.66 4.49 Elevated Stage 0/I sarcoidosis
6 54 II 0.95 3.23 Elevated Stage 0/I sarcoidosis
7 70 ID 1.96 2.61 Elevated Stage II/III sarcoidosis
8 75 DD 2.31 1.47 Normalized Stage II/III sarcoidosis
9 75 DD 2.31 1.47 Normalized Histiocytosis X
10 80 DD 2.64 1.81 Normalized Stage 0/I sarcoidosis
11 70 DD 1.99 1.13 Normalized Extrinsic allergic alveolitis
Z-scores greater than 1.96 are regarded as elevated ACE levels.
Conventional reference interval: 9–70U/l (calculated as 1.96 and +1.96 SD in our healthy population).
yACE activity based on ACE I/D-corrected reference interval relative to conventional reference interval.
zStage 0/I sarcoidosis ¼ normalized or improved towards radiographic stage I; stage II/III sarcoidosis ¼ persistent stage II/III or
progression towards this stage.
A. Kruit et al.514Additional factors that signiﬁcantly inﬂuence the normal
levels of an analyte in a given individual necessitates the use
of reference values that are corrected for those factors. The
inconvenience of adopting a multitude of reference inter-
vals speciﬁc for genotype and possibly other factors can be
avoided by utilizing the Z-score approach. This way, and as
demonstrated in this study, reporting a laboratory para-
meter as a Z-score is a pragmatic way of anticipating the
increasing number of reference intervals as a result of
genetic polymorphisms that lead to differential analyte
concentrations. Moreover, changes in pre-analytical proce-
dures or analytical methods do not necessarily lead to a
change of values and the Z-score may thus prevent the
introduction of new reference intervals in the clinic.
Only one effort to establish genotype-corrected ACE
reference values has been reported for white Caucasians.8
This study was aimed at the improvement of the identiﬁca-
tion of sarcoidosis patients when ACE genotypes were
considered. The authors suggested that more intricate
studies should be undertaken to establish a genotype-
corrected reference interval for any particular population.
A more elaborate study was undertaken using Japanese
healthy subjects and the obtained reference interval
depending on ACE I/D genotypes also made it clear that
for II genotype individuals in particular, a seemingly
moderate ACE elevation could lead to overlooking the
activity of sarcoidosis and that healthy DD genotype
individuals could easily be identiﬁed as having abnormal
(elevated) ACE levels.7 Similar to what we have shown here,
both authors clearly illustrated the importance of genotype
for reference values by reporting an immense increase of
sensitivity compared to the conventional reference interval.
In our study, variance analysis showed that the ACE I/D
genotype accounted for 34.0% of variation of ACE levels in
the control population. This was in accordance with previousreports which focused on I/D polymorphisms and additional
putative quantitative trait loci (QTLs).6,31–33
As pointed out by Csaszar et al.,34 who repeated the study
by Sharma et al. in a Hungarian population, genotype-
corrected reference values for ACE should be established
locally. A suggested standard reference interval, as provided
by the manufacturers of ACE measuring assays, will not
apply, given the fact that I/D allele frequencies can differ
vastly between ethnicities. Indeed, compared to Cauca-
sians,32,35,36 and conﬁrmed by our data, which show that the
D and I allele distributions are roughly the same (52% and
48%, respectively), the I allele in Japanese is more abundant
than the D allele and thus attributable to the lowering of the
overall reference range for ACE levels in Japanese.Conclusion
In conclusion, ACE I/D-corrected ACE activity in a Dutch
Caucasian population has shown that a relatively simple
genetic proﬁle can provide a more precise reference
interval. Reporting laboratory results in a way in which
reference intervals are incorporated may be a simple and
generally applicable approach for dealing with the increas-
ing number of genotype-corrected reference intervals for
other analytes.Acknowledgements
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